Likewise, Edwards and colleagues (2018) measured the frequency of CD103+ CD8+ TILs before and after anti-PD1 treatment in patients with metastatic melanoma and found that this subgroup expanded following ICB therapy in a very small cohort of responder patients [81]. The gene discussed is CD8A; the disease is metastatic melanoma.